Meeting Posters

Remote assessment of cognition with the unsupervised version of the Cogstate Brief Battery: Association of composite endpoints with Alzheimer’s disease biomarkers (Abstract)

Sink
21st Annual Scientific Meeting

Forecasting of change in speech function using remote assessment of acoustics (Abstract)

Simmatis
21st Annual Scientific Meeting

Precision functional mapping trials – A biomarker platform for neuropsychiatric drug development (Abstract)

Siegel
21st Annual Scientific Meeting

Development of the subject-rated Comprehensive Drug Withdrawal Scale (CDWS) to evaluate the physical dependence potential of investigational drugs (Abstract)

Setnik
21st Annual Scientific Meeting

Cannabis use in pregnant females: Importance for a need of biomarker for perinatal cannabis use (Abstract)

Satodiya
21st Annual Scientific Meeting

Implementing biomarker frameworks of Alzheimer’s and vascular disease trials to reduce cognitive decline in type 2 diabetes mellitus (Abstract)

Ruthirakuhan
21st Annual Scientific Meeting

Psilocybin-occasioned mystical-type experience predicts less heavy drinking in patients with alcohol use disorder (Abstract)

Petridis
21st Annual Scientific Meeting

Using exploratory graph analysis (EGA) to determine the role of insight on SIGH-D administration in an open-label trial (Abstract)

Namaky
21st Annual Scientific Meeting

Qualification plan for the PSYCHS as a COA for attenuated positive symptoms in patients at clinical high risk for psychosis (Abstract)

Mourgues Codern
21st Annual Scientific Meeting

Examining patterns of commonly observed quality issues across global schizophrenia clinical trial research sites (Abstract)

Micaletto
21st Annual Scientific Meeting

Speech measures associated with the course of symptoms severity in patients with MDD (Abstract)

Menne
21st Annual Scientific Meeting

The impact of PANSS change in screening on week 1 PANSS change in acute schizophrenia clinical trials (Abstract)

Kott
21st Annual Scientific Meeting

Predicting disease progression trajectories in individuals with amyotrophic lateral sclerosis using multimodal digital biomarkers (Abstract)

Kothare
21st Annual Scientific Meeting

Online advertising resulted in more educated participants and non-inferior screen fail rates when compared to offline methods in an Alzheimer’s disease clinical trial (Abstract)

Huoh
21st Annual Scientific Meeting

Insights to action: A tech-enabled operational monitoring and reporting framework to achieve high adherence in clinical trials (Abstract)

Gross
21st Annual Scientific Meeting

Clinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials (Abstract)

Gold
21st Annual Scientific Meeting

Predictive biomarker discovery in schizophrenia using advanced machine learning to decode heterogeneity: Analysis of the CATIE schizophrenia trial (Abstract)

Geraci
21st Annual Scientific Meeting

Novel machine learning approach outperforms traditional approaches in major depressive disorder clinical trials: Identifying subpopulations based on treatment response (Abstract)

Geraci
21st Annual Scientific Meeting

A novel asynchronous video technology and service to secure protocol compliance in a phase 2 major depressive disorder trial (Abstract)

Elmi
21st Annual Scientific Meeting

Speech-based quality analysis in COA administration: Profiling clinician behaviors in MADRS interviews (Abstract)

Efstathiadis
21st Annual Scientific Meeting